Inventor · disambiguated record
Peter Goekjian
Also filed as: GOEKJIAN PETER · GOEKJIAN PETER G · GOEKJIAN PETER GREGORY
7 granted patents·2 pending applications·77 citations·filing 1997–2022
78Inventor score
Files withINST NAT SANTE RECH MED2UNIVERSITA' DEGLI STUDI DI MILANO—BICOCCA2BELMONT PHILIPPE OLIVIER1GAMBACORTI PASSERINI CARLO1LILLY CO ELI1
Top patents by PatentIndex Score
9 records- 0185US8895744B2Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-AblGAMBACORTI PASSERINI CARLO·Filed 2009·Granted Nov 25, 2014·34 cites·11 claims
- 0273US5936084AHalo-substituted bisindolemaleimide protein kinase C inhibitorsLILLY CO ELI·Filed 1997·Granted Aug 10, 1999·43 cites·26 claims
- 0347US2024116923A1Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell deathSEABELIFE·Filed 2022·Application pending·0 cites
- 0439US2011112110A1Antiproliferative compounds and therapeutic uses thereofUNIV MILANO BICOCCA·Filed 2009·Application pending·0 cites
- 0537US10426758B2Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosisINST NAT SANTE RECH MED·Filed 2016·Granted Oct 1, 2019·0 cites·21 claims
- 0635US8999955B2Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biologicalBELMONT PHILIPPE OLIVIER·Filed 2009·Granted Apr 7, 2015·0 cites·15 claims
- 0734US9428500B2Alpha-carbolines for the treatment of cancerUNIVERSITA' DEGLI STUDI DI MILANO—BICOCCA·Filed 2013·Granted Aug 30, 2016·0 cites·13 claims
- 0832US10457678B2Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosisINST NAT SANTE RECH MED·Filed 2016·Granted Oct 29, 2019·0 cites·19 claims
- 0931US9708279B22-acylaminothiazoles for the treatment of cancerUNIVERSITA′ DEGLI STUDI DI MILANO-BICOCCA·Filed 2014·Granted Jul 18, 2017·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Peter Goekjian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →